ondasdechoque.org
PT-BR

Temporomandibular pain: pooled benefits with reporting conflicts · Review · 2026

Does shockwave help jaw joint pain and mouth opening?

In this review, jaw pain eased more with shockwave than with comparison treatments across 17 trials (1,036 people), and the mouth opened about 4 mm wider on average. Scores for overall jaw function ended about the same in both groups.

Eased jaw pain more than comparison care
trials in the pain results
17
people in the pain results
1,036
results pooled: pain, mouth opening and jaw function
3

Good to know: Treatments and comparisons varied between trials.

Chen L, Luo Y, Zhang L, et al. Front Rehabil Sci, 2026 · Read the paper ↗

How this study worked

17 studies1,036 peopleOne answer
A review gathers earlier studies to answer one question.

What happened

studies
17
people
1,036
Compared with
Active rehabilitation, medicines, sham treatment or no treatment, depending on the trial

Jaw pain compared with other treatments

Standardised difference across pain scales · below zero means less pain with shockwave

Across 17 trials with 1,036 people, jaw pain was lower with shockwave than with comparison treatments.
Show the numbers
Difference (standardised difference (no units))likely range
Jaw pain−1.28−1.96 to −0.61

What the trials used

Protocol reporting
ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.

Who took part

People with jaw joint and jaw muscle disorders (temporomandibular disorders), mostly in single-centre trials in China.

Side effects

The authors mention brief redness or discomfort.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Reported total 1,150 participants; pain 17 studies/1,036, opening 12/823, dysfunction 13/850. Mostly Chinese single-centre trials. Sex totals 509+601=1,110, not 1,150, and Table 1 reverses labels. Reference 40 is 2016 despite stated 2018–2025 inclusion range.

Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS)1 reported outcome
01
Post-treatment, varying trial timepoints

Pain: forest-plot SMD

Visual Analogue Scale (VAS) or Numerical Rating Scale (NRS) standard deviations

SMD-1.28CI 95% -1.96 to -0.61p = 0.0002

ESWT versus study-specific controls

17 studies · 1,036 participants in this estimate · I²=95%

Pooled random-effects estimate

-2.2Equal results 00.2

Forest plot explicitly uses SMD, not VAS points; text/table mislabel MD. Plot p=.0002 conflicts with text p<.00001.

Analysis details and source

Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.

Maximal mouth opening1 reported outcome
02
Post-treatment, varying trial timepoints

Maximal mouth opening

Maximal mouth opening mm

MD3.76CI 95% 1.52 to 5.99p = 0.0010

ESWT versus study-specific controls

12 studies · 823 participants in this estimate · I²=97%

Pooled random-effects estimate

-0.7Equal results 06.7

Positive difference means greater opening in ESWT; printed favors-axis labels are inconsistent with this direction.

Analysis details and source

Source-reported random-effects estimate; no recalculation.

Dysfunction index1 reported outcome
03
Post-treatment, varying trial timepoints

Dysfunction index

Dysfunction index index units

MD-0.05CI 95% -0.13 to 0.03p = 0.22

ESWT versus study-specific controls

13 studies · 850 participants in this estimate · I²=99%

Pooled random-effects estimate

-0.1Equal results 00

Interval crosses zero; no clear dysfunction benefit despite pain/opening signals.

Analysis details and source

Source-reported random-effects estimate; no recalculation.

Exploratory duration subgroups1 reported outcome
04
As reported in the article

Exploratory duration subgroups

Qualitative finding

Table 2 reports ≤2 weeks −0.79 [−1.38, −0.20] versus ≥4 weeks −1.79 [−2.09, −1.49], subgroup p = 0.003. Metric is labelled MD but main pain figure is SMD; do not prescribe duration from this ecological comparison. Table 2 subgroup interactions were null for shock count (p = 0.82) and sex composition (p = 0.79).

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
Protocol reporting

ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.

HARMS & TOLERABILITY

Discussion describes transient redness/discomfort, but the review gives no systematic adverse-event counts or pooled harm analysis. A favorable safety conclusion exceeds the presented safety data.

LIMITS OF THE ANALYSIS

Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.
Research review

Source-linked critical reading

clinical synthesis

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. External supplements not supplied with the intake were not read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Systematic review/meta-analysis of 18 trials, searched seven databases through December 2025. Random-effects pooling combined differing treatments and controls. Methods call bias assessment RoB2, while Results and figures use seven older-style domains and unclear-risk terminology.

Participants and setting

Reported total 1,150 participants; pain 17 studies/1,036, opening 12/823, dysfunction 13/850. Mostly Chinese single-centre trials. Sex totals 509+601=1,110, not 1,150, and Table 1 reverses labels. Reference 40 is 2016 despite stated 2018–2025 inclusion range.

Treatment

ESWT alone or combined with physical therapy, medicines or traditional Chinese interventions. Main PDF does not supply a complete study-by-study device/energy/session table; no pooled regimen can be recommended.

Comparison

Active rehabilitation, drugs, sham or no intervention were allowed. Combining add-on and replacement contrasts obscures how much benefit is specifically attributable to waves.

Outcomes and timing

Pain VAS/NRS, maximal interincisal opening and dysfunction index after treatment. Figure 4 reports standardized mean differences for pain, although text calls them MD on 0–10 VAS. Keep the forest-plot metric rather than treating −1.28 as VAS points.

What the results show

Figure 4: pain SMD −1.28 (95% CI −1.96 to −0.61), p = 0.0002, I² = 95%; text incorrectly prints p < 0.00001. Opening MD 3.76 mm (1.52 to 5.99), p = 0.001, I² = 97%; Figure 5 favors labels oppose higher-is-better direction. Dysfunction MD −0.05 (−0.13 to 0.03), p = 0.22, I² = 99%: no clear difference.

Harms

Discussion describes transient redness/discomfort, but the review gives no systematic adverse-event counts or pooled harm analysis. A favorable safety conclusion exceeds the presented safety data.

Limits and disclosures

Extreme heterogeneity, inadequate allocation/masking reporting, inconsistent metric and significance labels, incomplete trial characteristics and unverified MCID assertions. RoB framework and demographic inconsistencies reduce confidence; external supplements unavailable locally. No funding/conflicts declared. References 29/30 do not match the claimed Cochrane/PRISMA guidance.

Application to care

The review suggests possible short-term pain/opening benefits, but source inconsistencies prevent confident point-scale interpretation or a preferred-treatment recommendation. Null dysfunction matters for daily function.

What remains to be tested

Reconcile every trial, metric and figure direction against original data, report reproducible doses, separate sham and active-control contrasts, and use prespecified long-term outcomes and GRADE.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal shock wave therapy for temporomandibular disorders: efficacy on pain, maximal mouth opening, and dysfunction—a meta-analysis of randomized controlled trials

Chen L, Luo Y, Zhang L, Zhang X, Chen Y, Hu D. · Front Rehabil Sci · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →